Adderall XR and Rosuvastatin Interaction: What You Need to Know

Why This Combination Comes Up

Attention-deficit/hyperactivity disorder (ADHD) and dyslipidemia frequently coexist in adults. ADHD affects approximately 4.4% of U.S. adults according to the National Comorbidity Survey Replication (Kessler et al., 2006). Statin therapy, meanwhile, is prescribed to over 40 million Americans for cardiovascular risk reduction. Rosuvastatin (brand name Crestor) ranks among the most commonly dispensed statins due to its potent LDL-lowering efficacy. A 2019 analysis published in the Journal of the American Heart Association found that statin use among adults aged 40 to 75 reached 26% (Salami et al., 2017). Given these prevalence figures, co-prescription of Adderall XR and rosuvastatin is common. Patients and pharmacists rightly want clarity on whether a meaningful interaction exists.

The short answer: no direct drug-drug interaction has been documented. But the pharmacology behind that answer is worth understanding, because both drugs carry cardiovascular considerations that require attention when used together.

How Adderall XR Is Metabolized

Mixed amphetamine salts undergo hepatic metabolism primarily through cytochrome P450 2D6 (CYP2D6), with additional contributions from CYP1A2, CYP2B6, and CYP3A4. The FDA-approved prescribing information for Adderall XR describes oxidative deamination, aromatic hydroxylation, and conjugation as the principal metabolic routes. Renal excretion accounts for a significant fraction of elimination, with urinary pH influencing clearance. Acidic urine accelerates amphetamine excretion; alkaline urine slows it.

CYP2D6 polymorphisms affect amphetamine metabolism. Poor metabolizers (roughly 5 to 10% of Caucasian populations) may experience higher plasma concentrations at standard doses (Bradford, 2002). This matters for interaction screening because any co-administered drug that inhibits CYP2D6 could theoretically raise amphetamine levels. Rosuvastatin does not inhibit CYP2D6. It does not inhibit CYP3A4, CYP1A2, or CYP2B6 either, according to its label. That eliminates the primary enzymatic pathway for a pharmacokinetic interaction.

How Rosuvastatin Is Metabolized

Rosuvastatin stands apart from most statins because it undergoes minimal cytochrome P450 metabolism. Approximately 90% of the drug is excreted unchanged, primarily through bile and feces. The small fraction that is metabolized involves CYP2C9 to a limited extent, with CYP2C19 playing a negligible role (FDA Crestor label).

What makes rosuvastatin's pharmacokinetics distinctive is its dependence on membrane transporters rather than CYP enzymes. Rosuvastatin is a substrate of organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, and breast cancer resistance protein (BCRP). Drugs that inhibit these transporters can raise rosuvastatin plasma concentrations, sometimes dramatically. Cyclosporine, for example, increases rosuvastatin AUC by approximately 7-fold through OATP1B1 inhibition (Simonson et al., 2004). The 2018 FDA guidance on transporter-mediated drug interactions emphasizes that OATP inhibition is the primary clinical concern with rosuvastatin co-administration (FDA Drug Interaction Guidance).

Amphetamines have not been shown to inhibit OATP1B1, OATP1B3, or BCRP in any published in vitro or clinical study. No transporter-based interaction mechanism exists between these two drugs.

The Cardiovascular Overlap That Does Matter

The absence of a pharmacokinetic interaction does not mean there is zero clinical consideration. Both medications affect the cardiovascular system, and the pharmacodynamic overlap deserves monitoring.

Adderall XR raises blood pressure and heart rate through sympathomimetic activity. The prescribing information reports mean systolic blood pressure increases of 2 to 4 mmHg and heart rate increases of 3 to 6 bpm in clinical trials. For most patients with well-controlled hypertension or normal baseline blood pressure, these changes are modest. But in patients with pre-existing cardiovascular disease, uncontrolled hypertension, or structural cardiac abnormalities, the American Heart Association recommends careful cardiovascular assessment before starting stimulant therapy (Vetter et al., 2008).

Rosuvastatin is prescribed specifically to reduce cardiovascular risk. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg daily reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death by 44% compared to placebo in patients with elevated high-sensitivity C-reactive protein (Ridker et al., 2008). Patients taking both drugs are often doing so because they carry cardiovascular risk factors that require lipid management, making the hemodynamic effects of stimulants clinically relevant.

The practical framework: these drugs do not interact pharmacokinetically, but the patient taking both may need tighter cardiovascular monitoring than a patient taking either drug alone. Blood pressure checks at each ADHD follow-up visit and lipid panels every 6 to 12 months represent reasonable clinical practice.

Muscle-Related Side Effects: Sorting Signal from Noise

Patients sometimes worry about muscle pain when taking statins alongside other medications. Statin-associated muscle symptoms (SAMS) affect an estimated 7 to 29% of statin users depending on the definition used, according to a 2015 European Atherosclerosis Society consensus statement (Stroes et al., 2015).

Amphetamines are not associated with myopathy or rhabdomyolysis through statin-potentiating mechanisms. The drugs that increase statin-related muscle risk typically do so by raising statin plasma levels through CYP3A4 inhibition (relevant for atorvastatin, simvastatin, and lovastatin) or OATP inhibition (relevant for rosuvastatin and pitavastatin). Since amphetamines affect neither pathway, co-administration should not increase rosuvastatin muscle toxicity risk.

If a patient reports new muscle pain after starting both medications, standard workup applies: check creatine kinase (CK) levels, assess for hypothyroidism, and evaluate exercise patterns. Attributing the symptoms to a drug-drug interaction between these two specific agents is not supported by the literature.

Statin Selection Considerations for ADHD Patients

Not all statins behave like rosuvastatin. If a patient takes Adderall XR and needs statin therapy, rosuvastatin and pitavastatin offer a theoretical advantage: neither depends heavily on CYP enzymes for clearance. By contrast, simvastatin and lovastatin are CYP3A4 substrates with longer lists of interacting drugs. Atorvastatin, while more forgiving than simvastatin, is also a CYP3A4 substrate.

The 2018 American College of Cardiology/American Heart Association cholesterol management guideline recommends moderate-to-high-intensity statin therapy based on cardiovascular risk category (Grundy et al., 2019). Rosuvastatin 20 to 40 mg qualifies as high-intensity therapy. Rosuvastatin 5 to 10 mg qualifies as moderate intensity. For patients already on Adderall XR, selecting rosuvastatin avoids introducing CYP-mediated interaction complexity altogether.

The guideline does not specifically address stimulant co-administration because there is no interaction requiring special guidance. Statin selection in ADHD patients should follow standard cardiovascular risk stratification.

Urinary pH and a Theoretical Footnote

One pharmacological curiosity deserves mention for completeness. Rosuvastatin, as a weak acid, could theoretically alter urinary pH if excreted renally in significant amounts. Urinary pH affects amphetamine clearance: alkaline urine decreases renal excretion, potentially prolonging amphetamine effect, while acidic urine accelerates clearance.

In practice, this is not clinically relevant for two reasons. First, rosuvastatin's renal excretion accounts for only about 10% of total elimination. Second, the magnitude of any pH shift from a statin at therapeutic doses would be negligible. Agents that meaningfully affect urinary pH include sodium bicarbonate, acetazolamide, and ammonium chloride. Rosuvastatin does not belong in that category.

The Adderall XR label warns about urinary pH interactions with "agents that alkalinize the urine" and specifically names sodium bicarbonate and acetazolamide. Statins are not listed. This theoretical pathway can be dismissed.

Monitoring Protocol for Co-Prescribed Patients

For patients taking Adderall XR and rosuvastatin concurrently, the following monitoring is appropriate based on each drug's individual label recommendations and guideline-based care:

At initiation of the combination:

• Baseline blood pressure and resting heart rate
• Fasting lipid panel (if not already obtained within 12 weeks)
• Hepatic transaminases (ALT) per rosuvastatin label recommendation
• Assessment for pre-existing muscle symptoms

Ongoing monitoring (every 3 to 6 months for the first year, then annually):

• Blood pressure and heart rate at every ADHD medication visit
• Lipid panel every 6 to 12 months to assess rosuvastatin efficacy
• Patient inquiry about new muscle pain, tenderness, or weakness
• CK measurement only if symptomatic (routine CK monitoring is not recommended by the ACC/AHA)

Red flags requiring prompt evaluation:

• Resting heart rate sustained above 100 bpm
• Blood pressure readings consistently above 140/90 mmHg (or above the patient's individualized target)
• Diffuse muscle pain with brown urine (suggesting rhabdomyolysis)
• New chest pain, palpitations, or syncope

This monitoring protocol is not specific to a drug-drug interaction between Adderall XR and rosuvastatin. It reflects the standard of care for each medication individually. The combination does not require additional monitoring beyond what each drug demands on its own.

What About Generic Mixed Amphetamine Salts?

Adderall XR is one brand of mixed amphetamine salts extended-release. Generic formulations contain the same four amphetamine salt forms (amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate) in the same 3:1 d-amphetamine to l-amphetamine ratio. The interaction profile with rosuvastatin is identical regardless of manufacturer.

The same applies to immediate-release mixed amphetamine salts (Adderall IR). The metabolic pathways are unchanged; only the release kinetics differ. Neither formulation introduces a new interaction mechanism with rosuvastatin.

Lisdexamfetamine (Vyvanse), a prodrug of dextroamphetamine, shares the same CYP2D6-mediated metabolic pathway and would carry the same non-interaction profile with rosuvastatin. Patients who switch between stimulant formulations do not need rosuvastatin dose adjustments.

Other Drugs That Actually Do Interact With Rosuvastatin

For context, the drugs that produce real, clinically significant interactions with rosuvastatin include:

• Cyclosporine: increases rosuvastatin AUC approximately 7-fold via OATP1B1 inhibition. The rosuvastatin label limits the dose to 5 mg daily with cyclosporine (FDA Crestor label).
• Gemfibrozil: increases rosuvastatin AUC approximately 1.9-fold via OATP1B1 inhibition and glucuronidation interference. Combination requires caution and dose limitation.
• Certain protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir): increase rosuvastatin exposure through OATP and BCRP inhibition. Dose caps of 10 mg daily apply.
• Regorafenib: inhibits BCRP-mediated rosuvastatin efflux, increasing exposure.

Amphetamines do not appear on any of these lists. The FDA label for rosuvastatin does not mention amphetamines, mixed amphetamine salts, or any CNS stimulant as an interacting drug.